Physician profile

Michael Hoosien

Clinical Cardiac Electrophysiology · Atlanta, GA

NPI 1134362627

$37,273.48

in general payments reported to CMS, 2019-2025

34 companies · $3,667 in 2025

The $3,667 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$6,507.37
Travel and Lodging$3,533.58
Consulting Fee$1,874.25

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $15,227.45 2019-2024 Xarelto
Biosense Webster, INC. $6,360.62 2019-2025 Carto 3, Qdot Micro Catheter, Octaray Mapping Catheter
Atricure, INC. $3,540.93 2021-2025 Epi-Sense Guided Coagulation System With Visitrax, Epi-Ease Epicardial Access System
Medtronic, INC. $3,216.51 2021-2025 Sphere-9, Affera Mapping System, Pulseselect
Cvrx, INC. $2,808.52 2020-2025 Barostim Neo System
Biotronik INC. $1,849.82 2024 Biomonitor, Acticor 7 Vr-T Dx, Solia
Abbott Laboratories $1,034.58 2019-2025 Aveir, Ensite, Jot Dx
Boston Scientific Corporation $921.47 2019-2025 Watchman Access System, Farawave, Fineline II Sterox
Ebr Systems, INC. $535.81 2025
Cardiva Medical, INC. $244.98 2022-2024 Cardiva Vascade Mvp Vvcs 6-12f, Ensoetm
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $219.94 2019-2025 Lifevest
Medtronic Vascular, INC. $196.50 2019-2020
Zoll Respicardia, INC. $165.53 2024 Remede System
Acutus Medical, INC. $159.74 2022-2023
Cordis US Corp. $91.79 2024-2025 Mynx Control, Mynx Control Venous, Mynx Venous Vcd
Show all 33 companies
CompanyGeneral paymentsYearsTop products
E.R. Squibb & Sons, L.L.C. $91.15 2021-2025 Eliquis, Camzyos
Impulse Dynamics (USA) INC. $91.07 2019-2024 Optimizer, Optimizer
Inspire Medical Systems, INC. $81.02 2024-2025 Inspire
Edwards Lifesciences Corporation $66.72 2023-2025 Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia
Pfizer INC. $42.47 2019-2020
Sanofi-Aventis U.S. LLC $42.33 2019-2023
Portola Pharmaceuticals, LLC $40.37 2019
Baxter Healthcare $34.17 2025
Novartis Pharmaceuticals Corporation $32.26 2024-2025
Philips North America LLC $26.55 2019
Astrazeneca Pharmaceuticals LP $24.75 2023 Andexxa
Vektor Medical INC. $24.03 2025 Vmap
Esperion Therapeutics, INC. $22.39 2025 Nexletol
Cardiofocus, INC. $18.27 2019
Boehringer Ingelheim Pharmaceuticals, INC. $17.79 2021
Irhythm Technologies, INC. $15.72 2023 Zio Xt Patch
Amgen INC. $14.42 2024 Repatha
Merck Sharp & Dohme LLC $13.81 2022

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Hoosien

$37,273.48

in general payments reported 2019-2025

Years
2019-2025
Top company
Janssen Pharmaceuticals, INC
Context
The $3,667 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).

https://glasscript.com/doctor/709302/michael-hoosien

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.